Propanc Biopharma Reports Nasdaq Uplisting and $4 Million Public Offering
I'm PortAI, I can summarize articles.
Propanc Biopharma Inc. announced its Nasdaq uplisting and a $4 million public offering. The company reported $17 million in total current assets and a $2 million reduction in liabilities for Q1 ending September 30, 2025. Net cash from financing activities was $2.53 million, with $600,000 in quarter-end cash. An initial $1 million tranche was received from a new $100 million private placement facility. The company is advancing its lead candidate, PRP, toward a Phase 1b clinical trial in 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments